Navigation Links
Alseres Pharmaceuticals, Inc. To Host Third Quarter 2008 Conference Call
Date:11/7/2008

herapies including bone repair. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia. The Company's lead molecular imaging product candidate is Altropane which is in Phase III clinical trials for the diagnosis of Parkinsonian Syndromes including Parkinson's Disease. The Company has research collaborations with Harvard Medical School and Children's Hospital Boston.

Forward-Looking Statements

The foregoing release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements include statements regarding Alseres' future expectations, beliefs, intentions, goals, strategies, plans or prospects regarding the future, including the development and commercialization of Altropane and Cethrin, the prospects of the Company's CNS and regenerative therapeutics programs, the Company's strategies to develop and commercialize axon regeneration technologies and the breadth of the Company's technologies and intellectual property portfolio. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2008 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Alseres from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Alseres Pharmaceuticals, Inc. to Present at New York Society of Security Analysts Conference
2. Alseres Pharmaceuticals, Inc. Raises $5 Million
3. Alseres Pharmaceuticals, Inc. Complies With NASDAQ Rule Regarding Recently Filed 10-K
4. Alseres Pharmaceuticals, Inc. to Present at The Neurotech Industry Investing & Partnering Conference
5. Alseres Pharmaceuticals to Host 2008 First Quarter Conference Call
6. Alseres Pharmaceuticals, Inc. Reports First Quarter 2008 Operational and Financial Results
7. Vista Partners Initiates Coverage on Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE)
8. Alseres Pharmaceuticals, Inc. Announces 2008 Annual Stockholders Meeting
9. Alseres Pharmaceuticals, Inc.s Chairman, Peter Savas, Reviews Companys Progress in its Annual Letter to Stockholders
10. Alseres Pharmaceuticals to Host 2008 Second Quarter Conference Call
11. Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company offering many ... it on Facebook, Twitter, and Pinterest. The fans will have ... a lottery every week. , Moreover, the company has extended ... Angelweddingdress homepage for more information. , Angelweddingdress ...
(Date:1/22/2015)... A new white paper by The Beryl ... the long-term care environment as well as provides recommendations ... paper, “The Power of Person-Centeredness in Long-Term Care: A ... the patient, resident and family experience in long-term care ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Joan Lunden, ... keynote speaker at the upcoming 32nd Annual Miami ... Physicians’ Education Resource®, LLC (PER®) , shares that ... have gone undetected if she had not followed up ...
(Date:1/22/2015)... Four years since the release of their debut recording Love is ... Avasa & Matthew Love – the duo are pleased to announce ... White Swan Records on February 24, 2015. , THE ROAD offers ... to all of us to walk out of the mire of ...
(Date:1/22/2015)... 2015 Compare-autoinsurance.org has released a new blog post ... auto insurance policy . , Some types of vehicles ... check the newly released blog post to see if their vehicle ... damaged vehicles are some of the cars that cannot be covered ...
Breaking Medicine News(10 mins):Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2
... Sept. 1 (HealthDay News) -- The intensity of exercise, not ... chances of living a longer life, a new study suggests. ... men with high levels of cycling intensity lived 5.3 years ... than men with low intensity. Among female cyclists, those ...
... DARIEN, IL A natural yellowing of the eye lens that ... group of test volunteers, according to a,study in the September 1 ... lens discoloration worsened with age, so did the risk of insomnia. ... explain why sleep disorders become more frequent with increasing age," said ...
... adults aged 15 to 44 increased up to 37% ... by researchers at the Centers for Disease Control and ... of Neurology , a journal of the American Neurological ... in the prevalence of hypertension, diabetes, obesity, lipid disorders, ...
... in the September issue of the Journal of the ... optimization in chest computed tomography (CT) scans. Chest CT is ... diagnose the cause of clinical signs or symptoms of the ... fever. Regardless of the body region being scanned, ...
... By Randy Dotinga HealthDay Reporter , WEDNESDAY, ... using electronic medical records instead of paper files could ... Diabetic patients "did better and improved faster" at ... e-records, said study author Dr. Randall D. Cebul, a ...
... WEDNESDAY, Aug. 31 (HealthDay News) -- A new type of ... tumor cells without harming normal cells is showing promise in ... 23 patients with advanced cancers that had spread to multiple ... received an intravenous infusion of a virus called JX-594 at ...
Cached Medicine News:Health News:Aging eyes linked to sleepless nights, new study shows 2Health News:Increased prevalence of stroke hospitalizations seen in teens and young adults 2Health News:Electronic Medical Records Might Boost Diabetes Care 2Health News:Electronic Medical Records Might Boost Diabetes Care 3Health News:Trial of Cancer-Fighting Virus Shows Promise 2Health News:Trial of Cancer-Fighting Virus Shows Promise 3
(Date:1/23/2015)... N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. ... its Phase I trial of Lixte,s lead compound, LB‑100, is ... John S. Kovach , M.D., the founder ... planned to be completed at a single site. Accrual of ...
(Date:1/23/2015)... JUNCTION, N.J. , Jan. 23, 2015  CytoSorbents ... company commercializing its CytoSorb® extracorporeal cytokine adsorber to ... patients, announced the receipt of $385,642, net of ... participant of the Technology Business Tax Certificate Transfer ...
(Date:1/23/2015)... and BOSTON , January 23, 2015 ... discovery and development company, is delighted to announce that the ... awarded to Miles Congreve (Vice President of Chemistry), ... Malcolm Weir (Chief Executive Officer and co-founder) for ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4
... at 8 am versus placebo: - 25,/ - ... Blood pressure reduction dependent on vaccine dose and ... today at the Seventeenth European,Meeting on Hypertension in ... Italy, June 17, 2007 -,Cytos Biotechnology AG (SWX:CYTN) ...
... WIRE)--Jun 18, 2007 - Advanced Viral,Research Corp. ... today that preliminary findings from its ongoing,Phase ... AVR118,appears to have clinical activity in reducing ... dermatologic,dermabrasion., The Phase II open label dermatological ...
Cached Medicine Technology:Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 2Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 3Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 4Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 5Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 6Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 7Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 8Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 9Advanced Viral Research Corp. Announces Positive Preliminary,Findings from Ongoing Phase II Dermatological Study 2
A rapid, convenient, qualitative method for detecting asymptomatic occult bleeding....
... die each year of colon cancer ... improvements (high contrast berium enema, colonoscopy, ... in the success rate of curative ... been achieved over the past two ...
... of guaiac as a test for the presence ... phenolic compounds present in guaiac to quinones, resulting ... blood is present, the heme portion of the ... catalyzing the release of oxygen from hydrogen peroxide ...
... elitewas designed to improve patient compliance. Its ... sample collection options make this fecal occult ... and complete. Diet guidelines are explained in ... which foods and drugs are okay and ...
Medicine Products: